Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Elacestrant, an estrogen receptor antagonist developed by the Italian company Menarini, was first approved for marketing by the U.S. FDA on January 27, 2023. Subsequently, it has b···【more】
Article source：Captain MedicineRelease date：2026-03-16Recommended：186
Elacestrant, while exerting its therapeutic effects, can also cause some side effects. Patients taking Elacestrant need to closely monitor their own condition.Side Effects of Elace···【more】
Article source：Captain MedicineRelease date：2026-03-16Recommended：195
Regarding the dosage of elacestrant, in addition to the recommended dose, appropriate dose adjustments should be made based on the patient's individual condition.Recommended Ad···【more】
Article source：Captain MedicineRelease date：2026-03-16Recommended：200
Elacestrant is an estrogen receptor antagonist developed by the Italian company Menarini. It received its first approval from the U.S. Food and Drug Administration (FDA) on January···【more】
Article source：Captain MedicineRelease date：2026-03-16Recommended：200
Capmatinib is a targeted therapy for non-small cell lung cancer with MET exon 14 skipping mutations. For patients using this drug, the most crucial concerns are undoubtedly the pur···【more】
Article source：Captain MedicineRelease date：2026-03-13Recommended：239
Capmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibitor that specifically inhibits MET receptors and the phosphorylation process of MET-mediated downstre···【more】
Article source：Captain MedicineRelease date：2026-03-13Recommended：310
Ixazomib, as a novel targeted therapy, blocks the growth and proliferation of tumor cells by inhibiting proteasome activity, providing an important treatment option for patients wi···【more】
Article source：Captain MedicineRelease date：2026-03-13Recommended：225
Ixazomib is an oral proteasome inhibitor primarily used clinically to treat multiple myeloma. As a novel targeted therapy, it inhibits proteasome activity, blocking tumor cell grow···【more】
Article source：Captain MedicineRelease date：2026-03-13Recommended：261
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor that was first approved by the U.S. FDA in November 2013 for the treatment of mantle cell lymphoma (MCL). It has b···【more】
Article source：Captain MedicineRelease date：2026-03-12Recommended：212
Ibrutinib (Imbruvica) is an oral Bruton's tyrosine kinase (BTK) inhibitor used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström's m···【more】
Article source：Captain MedicineRelease date：2026-03-12Recommended：197
Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of Bruton's tyrosine kinase. It is used to treat chronic lymphocytic leukemia, mantle cell lymphoma,···【more】
Article source：Captain MedicineRelease date：2026-03-12Recommended：206
Ibrutinib (Imbruvica) is a type of medication called a kinase inhibitor, used to treat several types of blood cancers, as well as a serious complication of allogeneic stem cell tra···【more】
Article source：Captain MedicineRelease date：2026-03-12Recommended：184
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended：[list:visits]2026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended：[list:visits]2026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended：[list:visits]2026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended：[list:visits]2026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended：[list:visits]2026-31-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended：[list:visits]2026-30-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
